Nishadil
Signup Signin
Delhi | 25°C (windy)
The Quiet Revolution: How One Pill Could Change the Game for Sickle Cell and Thalassemia Patients

The Quiet Revolution: How One Pill Could Change the Game for Sickle Cell and Thalassemia Patients
The Quiet Hum of Hope and High Stakes: Unpacking the Future of Huntington's Treatment

The Quiet Hum of Hope and High Stakes: Unpacking the Future of Huntington's Treatment
The FDA's Tightening Grip: A Crucible for Biotech's Biggest Bets

The FDA's Tightening Grip: A Crucible for Biotech's Biggest Bets
The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope

The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope
The CRISPR Crusade: Intellia's Ambitious Leap into the Heart of AML

The CRISPR Crusade: Intellia's Ambitious Leap into the Heart of AML
The CRISPR Horizon: Intellia's Bold Leap Into Our Genetic Future, One Edit at a Time

The CRISPR Horizon: Intellia's Bold Leap Into Our Genetic Future, One Edit at a Time
The Long Road to Hope: Anavex's Alzheimer's Drug Hits a Regulatory Wall

The Long Road to Hope: Anavex's Alzheimer's Drug Hits a Regulatory Wall
Monopar's Breakthrough in Wilson Disease: A New Dawn with AstraZeneca's Shadow

Monopar's Breakthrough in Wilson Disease: A New Dawn with AstraZeneca's Shadow
Biohaven's Breakthrough Bid: Navigating FDA Flexibility for Spinocerebellar Ataxia's Future

Biohaven's Breakthrough Bid: Navigating FDA Flexibility for Spinocerebellar Ataxia's Future
Unveiling the Shadowy Ethics: Former Pharma CEO's FDA Claims Spark Regulatory Outcry

Unveiling the Shadowy Ethics: Former Pharma CEO's FDA Claims Spark Regulatory Outcry
Load more..